ALNYLAM PHARMACEUTICALS, INC. Equity Securities, FV-NI
ALNYLAM PHARMACEUTICALS, INC. (ALNY) had Equity Securities, FV-NI of $0 as of 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments › Short-Term Investments
us-gaap:EquitySecuritiesFvNi · last filed 2026-02-12
- 2025-12-31: Equity Securities, FV-NI $0.00.
- 2025-09-30: Equity Securities, FV-NI $0.00.
- 2025-06-30: Equity Securities, FV-NI $0.00.
- 2025-03-31: Equity Securities, FV-NI $7.20M.
| Period end | Equity Securities, FV-NI |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-12 |
| 2025-09-30 | $0.00 10-Q · filed 2025-10-30 |
| 2025-06-30 | $0.00 10-Q · filed 2025-07-31 |
| 2025-03-31 | $7.20M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $8.16M 10-K · filed 2026-02-12 |
| 2024-09-30 | $8.32M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $9.89M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $11.26M 10-Q · filed 2024-05-02 |
| 2023-12-31 | $11.18M 10-K · filed 2025-02-13 |
| 2023-09-30 | $10.41M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $27.26M 10-Q · filed 2023-08-03 |
| 2023-03-31 | $25.86M 10-Q · filed 2023-05-04 |
| 2022-12-31 | $28.12M 10-K · filed 2024-02-15 |
| 2022-09-30 | $23.05M 10-Q · filed 2022-10-27 |
| 2022-06-30 | $30.90M 10-Q · filed 2022-07-28 |
| 2022-03-31 | $32.00M 10-Q · filed 2022-04-28 |
| 2021-12-31 | $66.97M 10-K · filed 2023-02-23 |
| 2021-09-30 | $72.55M 10-Q · filed 2021-10-28 |
| 2021-06-30 | $52.53M 10-Q · filed 2021-08-03 |
| 2021-03-31 | $56.97M 10-Q · filed 2021-04-29 |
| 2020-12-31 | $44.63M 10-K · filed 2022-02-10 |
| 2020-09-30 | $57.22M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $86.31M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $38.08M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $13.97M 10-K · filed 2021-02-11 |
| 2018-12-31 | $1.21M 10-K · filed 2020-02-13 |
| 2018-09-30 | $15.00M 10-Q · filed 2018-11-07 |
| 2018-06-30 | $12.04M 10-Q · filed 2018-08-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |